Jim Tananbaum is the chief executive officer of Foresite Capital. The company has an asset base of $1.1 billion. For the past 20 years, Jim has gained extensive experience and knowledge in building and investing in healthcare companies.
Previously, he co-founded two successful biopharmaceutical corporations as well as two renowned healthcare investment practices. Towards his final year at Harvard Medical School, he incorporated GelTex Pharmaceuticals. Notably, the corporation developed and marketed two drugs for less than $80 million. Presently, these drugs are generating $ 1 billion in revenues. Later, he sold GelTex for $1.6 billion. He then founded Theravance, Inc. The company’s spin-off is Theravance Biopharma, Inc. Combined they have a market cap of $2.75 billion.
Early in his career, the shrewd entrepreneur served as a partner at Sierra Ventures. He played an integral role in establishing the company’s investment practice. Notably, Jim founded Prospect Venture Partners II and III. In addition, the executive has been behind the success of many corporations, including Amerigroup, Jazz Pharmaceuticals, Healtheon and Amira Pharmaceuticals.
Jim Tananbaum is an alumnus of prestigious institutions of higher learning. He has a B.S.E.E and B.S. from Yale University. Jim holds an MBA and MS from Harvard Business School and MIT respectively. Tananbaum earned his MD from Harvard Medical School. Owing to his vast experience in the healthcare industry, Jim was appointed to serve on the President Advisory Counsel of Yale University. He has also been sitting on the visiting committees and advisory boards seeking to enhance the Harvard-MIT HST program.
In an article on Wired, since 2011, Foresite Capital’s strategy has been to develop innovative capital solutions that will aid in building category-defining corporations across diagnostics, therapeutics, healthcare services and devices. Recently, the healthcare growth equity company announced that it had recruited Dr. Molly He to serve as a venture partner. She is the former senior director of a renowned firm, Illumina.
With over 15 years of experience in genomic development and research, and pharmaceutical, Dr. Molly is expected to enhance the growth of Foresite Capital. At Illumina, she was mandated with the duty of augmenting the entity’s protein reagent improvements and innovation around the globe. Foresite Capital is headquartered in San Francisco. Under Tananbaum’s leadership, the company has continued to develop innovative solutions across all healthcare sectors.